PUBH 3100 Week 5 Screening Rationale Example

Course	PUBH 3100 Human Disease and Prevention
Week	Week 5
Paper type	Screening rationale
Length	About 1,010 words, 6 pages
Format	APA 7 student paper
School	Walden University
Program	BS in Public Health
Updated	October 2026

Free sample paper for PUBH 3100 Week 5

Should a State Fund Ultrasound Screening for Thyroid Cancer in Adults Without Symptoms? A Screening Rationale That Takes a Position and Then Tries to Break It With Lead Time, Length Bias and Overdiagnosis

Student Name

Walden University

PUBH 3100: Human Disease and Prevention

Instructor Name

Month Day, Year

What this page is doingThe title states the policy question and the three tests, which tells readers the rationale will defend its position by attacking it with the standard screening biases.

The Question

A composite state's health department has been asked by a patient advocacy group to fund neck ultrasound screening for thyroid cancer among adults aged 40 and older with no symptoms. The group points to rising thyroid cancer numbers, high survival among people whose cancers are found early and stories of cancers caught before they caused trouble. This rationale examines the request for the period it targets, the years when thyroid cancer, if present, produces nothing anyone would notice.

What this page is doingOpening with the advocates' case in their own terms sets up a fair test rather than a straw argument.

The Position

The department should not fund population ultrasound screening for thyroid cancer in adults without symptoms. National prevention guidance recommends against such screening, concluding that its harms outweigh its benefits (US Preventive Services Task Force, 2017). The rest of this rationale tries to break that position by taking the advocates' three strongest arguments seriously and testing each against the biases that affect screening evidence.

Argument One: Survival Is Excellent When Cancers Are Found Early

The Case

People whose thyroid cancers are found by ultrasound before symptoms have five-year survival close to 100%, better than people diagnosed after a lump or hoarseness appears. If screening finds cancers earlier and those people live longer after diagnosis, screening seems to work.

The Test: Lead Time

Survival is measured from diagnosis. Screening moves the date of diagnosis earlier without necessarily changing the date of death. A person diagnosed by ultrasound at 50 who would otherwise have been diagnosed at 58 and died at 80 of the same cause gains eight years of "survival" without living a day longer. That gain is lead time, not benefit. The only measure immune to lead time is mortality in the whole screened population compared with an unscreened one. In South Korea, where widespread thyroid ultrasound screening began in 1999, thyroid cancer diagnoses rose roughly fifteenfold between 1993 and 2011 while thyroid cancer deaths stayed essentially flat (Ahn et al., 2014). If screening had been finding deadly cancers early enough to cure them, deaths should have fallen. The survival argument does not break the position.

Argument Two: Screen-Detected Cancers Behave Well, Which Shows Screening Works

The Case

Cancers found by ultrasound are usually small, low-grade papillary cancers that respond well to treatment. Advocates read this as evidence that early detection catches cancer before it becomes dangerous.

The Test: Length Bias

Screening at one point in time is more likely to find slow-growing cancers, because they spend years in a detectable but symptomless state, than fast-growing ones, which may appear and cause symptoms between screens. A screened group will therefore contain more slow-growing cancers than a group diagnosed by symptoms, even if screening changes nothing. The good behavior of screen-detected cancers may reflect what screening tends to catch, not what screening does. This argument also fails to break the position.

Argument Three: Rising Cases Show a Growing Threat That Demands Action

The Case

Thyroid cancer incidence in the United States rose steeply for decades. Advocates argue that a growing disease needs a screening program.

The Test: Overdiagnosis

Overdiagnosis means finding a genuine cancer that, left alone, would have stayed silent until the person died of something else. In the United States, thyroid cancer incidence nearly tripled between 1975 and 2009, almost entirely from small papillary cancers, while mortality stayed stable (Davies & Welch, 2014). A disease whose detected cases rise sharply while deaths do not is the signature of overdiagnosis, not of a growing threat. Every overdiagnosed person faces surgery, often lifelong hormone replacement and the possibility of complications such as damage to the nerves controlling the voice, with no chance of benefit. Rather than breaking the position, the rising numbers strengthen it.

What this page is doingShowing that each advocate argument rests on one of the three biases turns the attempt to break the position into its strongest support.

What Would Break the Position

The position would fall, and the department should change course, if a randomized trial showed that ultrasound screening reduced thyroid cancer deaths in the whole screened group compared with an unscreened group, with harms that did not outweigh the gain. No such evidence currently exists, and given the very low mortality from thyroid cancer, such a trial would need to be very large. The department should say this openly, so that the advocacy group knows what evidence would change the decision.

The Harms Side of the Ledger

A screening decision weighs benefits against harms, and the harms of thyroid screening are concrete. Ultrasound finds many small nodules, most of them harmless, and each finding can lead to a needle biopsy. A cancer diagnosis usually leads to surgery to remove part or all of the thyroid gland. People who lose the whole gland need hormone replacement for life, and surgery carries risks of damage to the nerves that control the voice and to the glands that regulate calcium. Each of these harms falls on people whose cancer, in many cases, would never have harmed them. Because thyroid cancer deaths are rare and did not fall in the Korean experience, the benefit side of the ledger is small, while the harm side grows with every additional person screened. The balance tips further against screening the more widely it is offered.

What the Department Can Do Instead

The department can support prompt evaluation of people who do have symptoms, such as a growing neck lump, hoarseness or difficulty swallowing, and it can explain to the public why screening without symptoms is not recommended. Communicating the reasons, including the Korean experience, respects the advocates' concern while explaining the decision. The department can also offer to revisit the question if trial evidence on mortality appears, which shows the decision rests on evidence rather than cost alone.

Summary

The request to fund thyroid ultrasound screening rests on survival figures, the favorable behavior of screen-detected cancers and rising incidence. Each argument is explained by lead time, length bias or overdiagnosis. The position against funding survives the attempt to break it, and it would change only with mortality evidence from a randomized trial.

References

Ahn, H. S., Kim, H. J., & Welch, H. G. (2014). Korea's thyroid-cancer "epidemic": Screening and overdiagnosis. The New England Journal of Medicine, 371(19), 1765-1767. https://doi.org/10.1056/NEJMp1409841

Davies, L., & Welch, H. G. (2014). Current thyroid cancer trends in the United States. JAMA Otolaryngology-Head & Neck Surgery, 140(4), 317-322. https://doi.org/10.1001/jamaoto.2014.1

US Preventive Services Task Force. (2017). Screening for thyroid cancer: US Preventive Services Task Force recommendation statement. JAMA, 317(18), 1882-1887. https://doi.org/10.1001/jama.2017.4011

The Walden PUBH 3100 Week 5 instructions

Screening rationale assignments ask students to judge whether a screening program should be offered and to defend the judgment against the biases that make screening look better than it is. Instructors expect lead time, length bias and overdiagnosis to be explained accurately and applied to the specific condition, not just defined. Many prompts ask students to state a position early and then test it, so the paper shows reasoning in motion instead of a balance sheet. Students should cite the current national recommendation and the strongest evidence on mortality. Discussion of harms, such as false positives, biopsies and treatment complications, is expected, as is naming the result that would overturn the position. Choosing a condition where the evidence is clear-cut, either for or against screening, makes the biases easier to demonstrate.

How the PUBH 3100 Week 5 example is put together

The rationale describes a composite request from an advocacy group and states its position, citing the national recommendation. Three argument sections each present one advocate case and test it: survival after early detection against lead time, using South Korea's diagnosis and death trends; the favorable features of screen-found cancers against length bias; and rising U.S. incidence with stable mortality against overdiagnosis. A margin note explains how the attempt to break the position supports it. A harms section describes biopsy, surgery and lifelong hormone replacement. Sections state the evidence that would reverse the decision and what the department can do instead. The paper keeps the advocates' arguments in their own words before testing them.

PUBH 3100 Week 5 rubric: what earns full marks

Screening rationales are scored on accurate use of the biases, use of mortality evidence, attention to harms and intellectual honesty. The sample defines each bias in the context of thyroid cancer and shows how it explains an advocate argument, earning the core criterion. Using population mortality, the measure immune to lead time and length bias, shows sound reasoning. The harms section balances the analysis. Honesty credit comes from stating the advocates' case fairly and naming the result that would change the decision. Citations to the national recommendation and to published trend analyses support every claim. Format and references complete the marks. Papers that recite definitions of the biases without applying them typically fall short.

PUBH 3100 Week 5 help from the desk

Screening papers often define lead time, length bias and overdiagnosis in a list and stop. Instead, attach each bias to a specific argument someone would make for the program, and show how the bias explains it. Use deaths in the whole population as your main outcome. Describe the harms people experience after a positive result. State the recommendation of the national task force and its date. Say what evidence would change your mind. Our team will draft a first screening rationale for the condition you are given at no charge.

Get a PUBH 3100 Week 5 example written to your instructions

Upload the Week 5 prompt with the rubric and the screening program your section named, and the desk builds a rationale on that program with the same bias section. The first custom sample is free and comes back inside 24-48 hours. Programs with weaker evidence behind them make for a stronger paper, and the desk will say so before starting.

More PUBH 3100 papers and BS in Public Health samples

PUBH 3100 Week 5 questions, answered

Where can I find a free PUBH 3100 Week 5 sample paper?

This page presents the full Week 5 screening rationale on thyroid ultrasound screening, testing its position against lead time, length bias and overdiagnosis.

What is lead time bias?

Screening moves the date of diagnosis earlier, so survival counted from diagnosis grows even when the date of death does not move.

What is length bias in screening?

Screening is more likely to find slow-growing disease, which lasts longer in a detectable, symptomless state, so screen-detected cases look milder whatever screening does.

What is overdiagnosis?

Finding a genuine disease, often a small cancer, that would have stayed harmless for the rest of the person's life.

Is thyroid cancer screening recommended for adults without symptoms?

No. The US Preventive Services Task Force recommends against screening asymptomatic adults, concluding that harms outweigh benefits.